Rezolute

RZLTPhase 3

Redwood City, United StatesFounded 2010rezolutebio.com

Rezolute is a clinical-stage biotech focused on rare metabolic diseases, with its lead candidate, ersodetug, in two pivotal Phase 3 trials for congenital and tumor hyperinsulinism. The company's mission is to significantly improve the quality of life for patients and families affected by severe hypoglycemia. Despite a recent setback in its congenital HI trial, Rezolute is engaging with the FDA under Breakthrough Therapy Designation and continues to advance its tumor HI study, supported by a leadership team with deep expertise in rare disease drug development and commercialization.

Market Cap

$237.3M

Founded

2010

Focus

AntibodiesBiologics

RZLT · Stock Price

USD 2.481.40 (-36.08%)

Historical price data

AI Company Overview

Technology Platform

Rezolute's platform is based on ersodetug, a fully human monoclonal antibody that binds allosterically to the insulin receptor in peripheral tissues (liver, fat, muscle) to modulate insulin signaling and help maintain glucose homeostasis, offering a universal approach to treating hypoglycemia from various causes.

Pipeline Snapshot

5 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC + RZ358 (10 mg/kg) or ...	Congenital Hyperinsulinism	Phase 3
Ersodetug	Tumor Hyperinsulinism (Tumor HI)	Phase 3
RZ358 Sequential Group Cohort 1 + RZ358 Sequential Group Cohort 2 + RZ358 Sequen...	Congenital Hyperinsulinism	Phase 2
Experimental: Group 1 - 50mg RZ402 + Experimental: Group 2 - 200mg RZ402 + Exper...	Diabetic Macular Edema	Phase 2
Ersodetug (9 mg/kg) + SOC	Tumor-associated Hyperinsulinism (Tumor HI)	Pre-clinical

Opportunities

The primary growth opportunity lies in establishing ersodetug as the first universal therapy for hypoglycemia across all forms of hyperinsulinism, addressing a severe unmet need in both rare pediatric and niche adult oncology settings.

Success in the tumor HI trial could also open exploration in other conditions of insulin receptor overactivation.

Risk Factors

Key risks include the clinical and regulatory uncertainty following the failed Phase 3 sunRIZE trial in congenital HI, the ongoing need to generate positive data from the tumor HI trial, and the financial risk associated with funding further development as a pre-revenue company.

Competitive Landscape

Competition is primarily from suboptimal standard of care (diazoxide, octreotide, surgery). Ersodetug's key differentiation is its novel mechanism acting downstream at the insulin receptor, offering a potential universal, targeted biologic therapy for a condition with no approved disease-modifying drugs.